Jefferies lowered the firm’s price target on Cross Country Healthcare to $32 from $40 and keeps a Buy rating on the shares. The firm has “heard investor skepticism” on Cross Country due to headwinds in temp nurse staffing and thinks increasing attrition rates in MSP contracts “present a notable headwind.” However, the firm thinks earning expectations for the second half and 2024 “have now appropriately adjusted down,” the analyst added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CCRN: